Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

Item

http://www.wikidata.org/entity/Q34308370

Q34308370

about

Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients.Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis.Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract.A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay.Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma.Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.What treatment in 2017 for inoperable pancreatic cancers?Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer.Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

P2860

Q26830913-6C300FDE-CA98-4426-A636-278F8DD8FA35 Q28552789-C5E50FCC-FB74-4085-B46B-7BA0F865D611 Q33394190-2694EB9A-8569-4F21-A20A-BFD7DE96A17B Q33402271-48F4B558-D286-4324-9E05-597E15260B02 Q33425869-7A698113-7FB7-4956-A753-BF0360A4BF1D Q33426575-10050BE9-4760-444D-A007-E8181CAE09A8 Q33606097-6E690744-268D-4BD2-8D1E-75FD369E3FC8 Q33672571-445B4587-6578-4260-85F4-77C951D16F3A Q33823212-1FE184EB-FF56-46CF-837B-A60593C5E2AA Q34342960-248BEEB7-2890-4A2D-AF6E-28D109F07C3E Q34404088-1D93D736-610F-4FBF-A903-74E7592FE7DE Q34631279-E0A7F2B8-58B8-481C-8FB4-432172AD52BD Q35828693-C087838C-3208-4262-A85F-C003D66BDB70 Q36035888-B3FF515E-4388-444B-B171-C4515AFECA27 Q36131174-5A7D17C9-2C75-4036-9B47-DF8C88C094B0 Q36214563-7BA51D48-0EA1-4E42-B190-574E69C33D1D Q36505264-22072502-AA6B-476C-BE4D-97548A10B0B8 Q36747372-0506E89A-226F-4243-A91E-544EF6BEFC50 Q37032865-9F635430-C119-4855-B6AE-ECF9EC7B9ADA Q38204280-3B3BAAEC-A866-4315-A041-FCEE26ECD868 Q38689025-64A99890-5732-4EEC-8300-D8553A7336D7 Q39001305-B43D5DE2-1FC5-4C6C-BD1C-B1E791B34EE7 Q39233456-58590DD3-7C05-4439-BB62-766D421980D6 Q47112954-324DBFEC-9807-498B-A972-A7B1F826DF0D Q58799265-DC8717B9-013E-4FA5-B37F-1648EF42688E

P2860

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

Item

http://www.wikidata.org/entity/Q34308370

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu